Navigation Links
StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
Date:11/11/2010

COVINA, Calif., Nov. 11, 2010 /PRNewswire/ -- StemCyte, Inc., one of the world's preeminent umbilical cord blood (UCB) banks and biotherapy companies, is proud to announce that the Company has been awarded two cash grants totaling $488,950 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program designed to support biomedical research by firms with fewer than 250 employees.

The Patient Protection and Affordable Care Act of 2010 (PPACA) created the QTDP program as a means to support qualified research and development projects that show significant potential to produce new and cost-saving therapies, support job growth and increase U.S. competitiveness.  Following a competitive application process, StemCyte was awarded two grants for advance therapies using UCB stem cells for the potential treatment of chronic spinal cord injury and chronic stroke.

"We are very pleased to have been awarded these grants and believe it reflects positively on the Advanced Therapeutic applications of cord blood stem cells that we continue to pursue," said Ken Giacin, StemCyte, Inc's Chairman and CEO.  "These awards reaffirm our belief that our UCB-related research has great potential for saving and improving lives."

The Internal Revenue Service issued the QTDP awards and will administer the program.  The QTDP program is designed to provide grants and tax credits to qualified biotechnology companies with fewer than 250 employees that demonstrate the potential to develop new therapies to treat chronic condition, address unmet medical needs, reduce health care costs, and advance the goal of curing cancer within 30 years.

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world.  StemCyte has supplied over 1,300 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers.  StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies.  They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, as well as supporting trials investigating regenerative spinal cord therapies.  They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units.  Its headquarters are located in Covina, Ca. and Ewing, NJ.  To learn more visit www.StemCyte.com.


'/>"/>
SOURCE StemCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
2. Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer
3. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
4. Catapult Systems Awarded SharePoint 2010 and FAST Intranet Project
5. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
6. Lentigen Awarded $1.2 Million by U.S. Government Under the Qualifying Therapeutic Discovery Project
7. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
8. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
9. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
10. Federal nanotechnology renewal grant awarded to ASU faculty
11. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/22/2016)... Md. , June 22, 2016  The American College ... Trade Show Executive Magazine as one of the ... on May 25-27 at the Bellagio in Las ... on the highest percentage of growth in each of the ... of exhibiting companies and number of attendees. The 2015 ACMG ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):